@article{BohnertMonoranuSiauwetal.2020,
  author    = {Bohnert, S. and Monoranu, C. - M. and Siauw, C. and Al-Tinawi, F. and Bohnert, M.},
  title     = {T{\"o}dliche Hirnmassenblutung infolge Vitamin-K-Mangels bei einem 9 Wochen alten S{\"a}ugling},
  series = {Rechtsmedizin},
  volume    = {30},
  journal   = {Rechtsmedizin},
  issn      = {0937-9819},
  doi       = {10.1007/s00194-020-00387-z},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-232475},
  pages     = {175-179},
  year      = {2020},
  abstract  = {Intrakranielle Blutungen sind im S{\"a}uglingsalter seltene, aber lebensbedrohende Ereignisse. Neben Gef{\"a}ßmissbildungen, Stoffwechseldefekten sowie St{\"o}rungen der Blutgerinnung kommen v. a. nichtakzidentielle Traumata, Sch{\"u}tteltrauma in Betracht. Die klinische Diagnostik umfasst hinsichtlich der Blutungsgenese neben Sonographie und MRT als apparatives Verfahren auch eine Fundoskopie sowie laborchemische Analysen, insbesondere der Gerinnungsparameter. F{\"u}r die Blutgerinnung ist das fettl{\"o}sliche Vitamin K essenziell: Fr{\"u}he, klassische und sp{\"a}te Vitamin-K-Mangel-Blutungen werden dabei unterschieden. Um ein geh{\"a}uftes Wiederauftreten von Vitamin-K-Mangel-Blutungen bei Neugeborenen und jungen S{\"a}uglingen zu verhindern, bedarf es einer hinreichenden Aufkl{\"a}rung der Eltern. Eine Verweigerung der Prophylaxe scheint Folge einer weltanschaulich begr{\"u}ndeten Ablehnung der Schulmedizin und ein zunehmendes Ph{\"a}nomen in wohlhabenden Industriel{\"a}ndern zu sein.},
  language  = {de}
}
@article{SchuhmannKraftBieberetal.2019,
  author    = {Schuhmann, Michael K. and Kraft, Peter and Bieber, Michael and Kollikowski, Alexander M. and Schulze, Harald and Nieswandt, Bernhard and Pham, Mirko and Stegner, David and Stoll, Guido},
  title     = {Targeting platelet GPVI plus rt-PA administration but not α2β1-mediated collagen binding protects against ischemic brain damage in mice},
  series = {International Journal of Molecular Science},
  volume    = {20},
  journal   = {International Journal of Molecular Science},
  number    = {8},
  issn      = {1422-0067},
  doi       = {10.3390/ijms20082019},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201700},
  year      = {2019},
  abstract  = {Platelet collagen interactions at sites of vascular injuries predominantly involve glycoprotein VI (GPVI) and the integrin α2β1. Both proteins are primarily expressed on platelets and megakaryocytes whereas GPVI expression is also shown on endothelial and integrin α2β1 expression on epithelial cells. We recently showed that depletion of GPVI improves stroke outcome without increasing the risk of cerebral hemorrhage. Genetic variants associated with higher platelet surface integrin α2 (ITGA2) receptor levels have frequently been found to correlate with an increased risk of ischemic stroke in patients. However until now, no preclinical stroke study has addressed whether platelet integrin α2β1 contributes to the pathophysiology of ischemia/reperfusion (I/R) injury. Focal cerebral ischemia was induced in C57BL/6 and Itga2\(^{-/-}\) mice by a 60 min transient middle cerebral artery occlusion (tMCAO). Additionally, wild-type animals were pretreated with anti-GPVI antibody (JAQ1) or Fab fragments of a function blocking antibody against integrin α2β1 (LEN/B). In anti-GPVI treated animals, intravenous (IV) recombinant tissue plasminogen activator (rt-PA) treatment was applied immediately prior to reperfusion. Stroke outcome, including infarct size and neurological scoring was determined on day 1 after tMCAO. We demonstrate that targeting the integrin α2β1 (pharmacologic; genetic) did neither reduce stroke size nor improve functional outcome on day 1 after tMCAO. In contrast, depletion of platelet GPVI prior to stroke was safe and effective, even when combined with rt-PA treatment. Our results underscore that GPVI, but not ITGA2, is a promising and safe target in the setting of ischemic stroke.},
  language  = {en}
}